<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>345</serviceExecutionTime><Drug id="12241"><DrugName>butorphanol tartrate (nasal spray), Cephalon</DrugName><DrugNamesKey><Name id="42778100">Stadol NS</Name><Name id="42981697">butorphanol</Name><Name id="42749781">butorphanol tartrate</Name></DrugNamesKey><DrugSynonyms><Name><Value>butorphanol tartrate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>(-)-butorphanol</Value></Name><Name><Value>BMY-12097</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Stadol NS</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>butorphanol tartrate (nasal spray), MDRNA/BMS/Cephalon</Value></Name><Name><Value>butorphanol</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>butorphanol tartrate (nasal spray), Cephalon</Value></Name><Name><Value>58786-99-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>42408-82-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18458">Adhera Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="15358">Cephalon Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="18458">Adhera Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12241" type="Drug"><TargetEntity id="91356" type="siDrug">Butorphanol tartrate</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15358" type="Company"><TargetEntity id="4295905909" type="organizationId">Cephalon Inc</TargetEntity></SourceEntity><SourceEntity id="18458" type="Company"><TargetEntity id="4295907254" type="organizationId">Adhera Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"></TargetEntity><TargetEntity id="10027599" type="MEDDRA"></TargetEntity><TargetEntity id="D008881" type="MeSH"></TargetEntity><TargetEntity id="-672899670" type="omicsDisease"></TargetEntity><TargetEntity id="27" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="287" type="Action"><TargetEntity id="270" type="Mechanism">Opioid Receptor Agonists</TargetEntity><TargetEntity id="2414" type="Mechanism">epsilon-Opioid Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Migraine - US - Oct-1994</FirstLaunched><FirstLaunched>Pain - US - Oct-1994</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="20">Pain</Indication><Indication id="210">Migraine</Indication></IndicationsPrimary><ActionsPrimary><Action id="287">Opioid receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="605">Nasal systemic formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2C</Code><Name>ANTI-MIGRAINE PREPARATIONS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-20T23:09:48.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-05-03T17:00:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15358" linkType="Company"&gt;Cephalon&lt;/ulink&gt; have developed and launched Stadol NS, a nasal spray formulation of the centrally-acting kappa opioid agonist, butorphanol tartrate, under a sublicensing agreement with &lt;ulink linkID="18458" linkType="Company"&gt;MDRNA&lt;/ulink&gt; (now Marina Biotech; formerly Nastech Pharmaceuticals), for the treatment of acute pain, including migraine. The formulation was launched in the US in October 1994 [&lt;ulink linkID="214915" linkType="reference"&gt;214915&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; was previously developed the drug  for the treatment of acute pain, including migraine. However by October 2004, the company had discontinued the drug development [&lt;ulink linkID="542693" linkType="Reference"&gt;542693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nastech (now MDRNA) was also developing an &lt;ulink linkID="47240" linkType="Drug"&gt;improved formulation of butorphanol tartrate&lt;/ulink&gt; [&lt;ulink linkID="371083" linkType="reference"&gt;371083&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 1991, the drug was approved by the US FDA for the treatment of pain [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;]. The formulation was launched in the US in October 1994 for the treatment of pain including migraine [&lt;ulink linkID="214915" linkType="reference"&gt;214915&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By 1995, the formulation was in clinical trials in Europe for migraine relief [&lt;ulink linkID="206604" linkType="reference"&gt;206604&lt;/ulink&gt;]. In one study, however, it was rated as poor by over half the patients tested [&lt;ulink linkID="187235" linkType="reference"&gt;187235&lt;/ulink&gt;], while it has also been said that the 3-month shelf-life might present a practical problem in patients with infrequent attacks [&lt;ulink linkID="187236" linkType="reference"&gt;187236&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The nasal formulation of butorphanol tartrate had the advantage of providing a rapid onset of analgesia (within 15 min) and was effective against postoperative pain [&lt;ulink linkID="187234" linkType="reference"&gt;187234&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2001, the US patent covering Stadol NS expired, and in April 2002 the international patent expired, therefore Nastech no longer received royalty payments after this time [&lt;ulink linkID="509245" linkType="reference"&gt;509245&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-10-01T00:00:00.000Z</StatusDate><Source id="214915" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-10-01T00:00:00.000Z</StatusDate><Source id="214915" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="210">Migraine</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="542693" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="542693" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18458">Adhera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-10-01T00:00:00.000Z</StatusDate><Source id="180181" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-12-01T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01453"><Name>Opioid receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18458">Adhera Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc2c(cc1O)[C@@]34CCCC[C@]3([C@@H](C2)N(CC4)CC5CCC5)O</Smiles><Smiles>c1cc2c(cc1O)[C@@]34CCCC[C@]3([C@@H](C2)N(CC4)CC5CCC5)O.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O</Smiles></StructureSmiles><Deals><Deal id="120153" title="Bristol-Myers Squibb to develop and market MDRNA's Stadol NS "></Deal><Deal id="128192" title="Cephalon to market MDRNA's butorphanol tartrate in the US"></Deal><Deal id="242997" title="Stadol NS nasal spray for pain in US"></Deal></Deals><PatentFamilies><PatentFamily id="2248915" number="WO-08203768" title="Novel Method Of Administering Narcotic Antagonists And Analgesics And Novel Dosage Forms Containing Same"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adhera Therapeutics Inc" id="18458"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Kentucky" id="20600"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>